Studies support carfilzomib’s approval
Bone marrow aspirate
showing multiple myeloma
Results from 3 multicenter clinical trials indicate that carfilzomib elicits good responses and manageable toxicities in both newly diagnosed and pretreated patients with multiple myeloma (MM).
Notify me when a comment is posted for this article
In This Section